BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 27105525)

  • 21. First in class dual MDM2/MDMX inhibitor ALRN-6924 enhances antitumor efficacy of chemotherapy in TP53 wild-type hormone receptor-positive breast cancer models.
    Pairawan S; Zhao M; Yuca E; Annis A; Evans K; Sutton D; Carvajal L; Ren JG; Santiago S; Guerlavais V; Akcakanat A; Tapia C; Yang F; Bose PSC; Zheng X; Dumbrava EI; Aivado M; Meric-Bernstam F
    Breast Cancer Res; 2021 Mar; 23(1):29. PubMed ID: 33663585
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.
    Tovar C; Graves B; Packman K; Filipovic Z; Higgins B; Xia M; Tardell C; Garrido R; Lee E; Kolinsky K; To KH; Linn M; Podlaski F; Wovkulich P; Vu B; Vassilev LT
    Cancer Res; 2013 Apr; 73(8):2587-97. PubMed ID: 23400593
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anticancer Effects of a New SIRT Inhibitor, MHY2256, against Human Breast Cancer MCF-7 Cells via Regulation of MDM2-p53 Binding.
    Park EY; Woo Y; Kim SJ; Kim DH; Lee EK; De U; Kim KS; Lee J; Jung JH; Ha KT; Choi WS; Kim IS; Lee BM; Yoon S; Moon HR; Kim HS
    Int J Biol Sci; 2016; 12(12):1555-1567. PubMed ID: 27994519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma.
    Lu J; Guan S; Zhao Y; Yu Y; Wang Y; Shi Y; Mao X; Yang KL; Sun W; Xu X; Yi JS; Yang T; Yang J; Nuchtern JG
    Oncotarget; 2016 Dec; 7(50):82757-82769. PubMed ID: 27764791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Curcumin, a dietary component, has anticancer, chemosensitization, and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway.
    Li M; Zhang Z; Hill DL; Wang H; Zhang R
    Cancer Res; 2007 Mar; 67(5):1988-96. PubMed ID: 17332326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The cholesterol metabolite 27-hydroxycholesterol regulates p53 activity and increases cell proliferation via MDM2 in breast cancer cells.
    Raza S; Ohm JE; Dhasarathy A; Schommer J; Roche C; Hammer KD; Ghribi O
    Mol Cell Biochem; 2015 Dec; 410(1-2):187-95. PubMed ID: 26350565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.
    Tovar C; Rosinski J; Filipovic Z; Higgins B; Kolinsky K; Hilton H; Zhao X; Vu BT; Qing W; Packman K; Myklebost O; Heimbrook DC; Vassilev LT
    Proc Natl Acad Sci U S A; 2006 Feb; 103(6):1888-93. PubMed ID: 16443686
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New small molecules, ISA27 and SM13, inhibit tumour growth inducing mitochondrial effects of p53.
    Sorriento D; Del Giudice C; Bertamino A; Ciccarelli M; Gomez-Monterrey I; Campiglia P; Novellino E; Illario M; Trimarco B; De Luca N; Iaccarino G
    Br J Cancer; 2015 Jan; 112(1):77-85. PubMed ID: 25422906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estrogen-activated MDM2 disrupts mammary tissue architecture through a p53-independent pathway.
    Kundu N; Brekman A; Kim JY; Xiao G; Gao C; Bargonetti J
    Oncotarget; 2017 Jul; 8(29):47916-47930. PubMed ID: 28615518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner.
    Feng FY; Zhang Y; Kothari V; Evans JR; Jackson WC; Chen W; Johnson SB; Luczak C; Wang S; Hamstra DA
    Neoplasia; 2016 Apr; 18(4):213-22. PubMed ID: 27108384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TIS21
    Sundaramoorthy S; Devanand P; Ryu MS; Song KY; Noh DY; Lim IK
    J Cancer Res Clin Oncol; 2018 Aug; 144(8):1445-1462. PubMed ID: 29808317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MicroRNA-340 inhibits prostate cancer cell proliferation and metastasis by targeting the MDM2-p53 pathway.
    Huang K; Tang Y; He L; Dai Y
    Oncol Rep; 2016 Feb; 35(2):887-95. PubMed ID: 26718483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models.
    Wang W; Qin JJ; Voruganti S; Srivenugopal KS; Nag S; Patil S; Sharma H; Wang MH; Wang H; Buolamwini JK; Zhang R
    Nat Commun; 2014 Oct; 5():5086. PubMed ID: 25271708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design and synthesis of new bioisosteres of spirooxindoles (MI-63/219) as anti-breast cancer agents.
    Kumar A; Gupta G; Bishnoi AK; Saxena R; Saini KS; Konwar R; Kumar S; Dwivedi A
    Bioorg Med Chem; 2015 Feb; 23(4):839-48. PubMed ID: 25618595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery, synthesis, and biological evaluation of orally active pyrrolidone derivatives as novel inhibitors of p53-MDM2 protein-protein interaction.
    Zhuang C; Miao Z; Zhu L; Dong G; Guo Z; Wang S; Zhang Y; Wu Y; Yao J; Sheng C; Zhang W
    J Med Chem; 2012 Nov; 55(22):9630-42. PubMed ID: 23046248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of MDM2 Re-Sensitizes Rapamycin Resistant Renal Cancer Cells via the Activation of p53.
    Tian X; Dai S; Sun J; Jiang S; Sui C; Meng F; Li Y; Fu L; Jiang T; Wang Y; Su J; Jiang Y
    Cell Physiol Biochem; 2016; 39(5):2088-2098. PubMed ID: 27825169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol (SQ0814061), a novel microtubule inhibitor, evokes G2/M cell cycle arrest and apoptosis in human breast cancer cells.
    Xu J; Zuo D; Qi H; Shen Q; Bai Z; Han M; Li Z; Zhang W; Wu Y
    Biomed Pharmacother; 2016 Mar; 78():308-321. PubMed ID: 26898456
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of the p53-MDM2 interaction by adenovirus delivery of ribosomal protein L23 stabilizes p53 and induces cell cycle arrest and apoptosis in gastric cancer.
    Zhang Y; Shi Y; Li X; Du W; Luo G; Gou Y; Wang X; Guo X; Liu J; Ding J; Wu K; Fan D
    J Gene Med; 2010 Feb; 12(2):147-56. PubMed ID: 20020415
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
    Hu B; Gilkes DM; Chen J
    Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
    Wang H; Yu D; Agrawal S; Zhang R
    Prostate; 2003 Feb; 54(3):194-205. PubMed ID: 12518324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.